Comparative Efficacy and Clinical Outcomes of Haploidentical Stem Cell Transplantation to Other Stem Sources for Treatment in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis

Cell Transplantation Volume 29: 1–15 © The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0963689720904965 journals.sagepub.com/home/cll

(\$)SAGE

Chutima Kunacheewa¹, Patompong Ungprasert², Ployploen Phikulsod¹, Surapol Issaragrisil¹, and Weerapat Owattanapanich¹

Abstract

The use of allogeneic hematopoietic stem cell transplantation (HSCT) is recommended during the first complete remission of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). However, only 30% of these cases have fully matched sibling donors (MSDs). Alternatively, matched unrelated donors (MUDs) and haploidentical (haplo) donors from first-degree relatives increase the access to transplantation, with some reported differences in outcomes. The current systematic review and meta-analysis was conducted with the aim of summarizing the results of those studies to compare the efficacy and toxicity of MSD-HSCT and MUD-HSCT versus haplo-HSCT for patients with AML or MDS. Articles published before September 15, 2018, were individually searched for in two databases (MEDLINE and EMBASE) by two investigators. The effect estimates and 95% confidence intervals (CIs) from each eligible study were combined using the Mantel-Haenszel method. A total of 14 studies met the eligibility criteria and were included in the meta-analysis. The overall survival rates were not significantly different between the groups, with pooled odds ratios of the chance of surviving at the end of the study when comparing haplo-HSCT to MSD-HSCT and comparing haplo-HSCT to MUD-HSCT of 0.85 (95% CI: 0.70 to 1.04; $l^2 = 0\%$) and 1.12 (95% CI: 0.89 to 1.41; $l^2 = 33\%$), respectively. The pooled analyses of other outcomes also showed comparable results, except for the higher grade 2 to 4 acute graft-versus-host disease (GvHD) for patients who received haplo-HSCT than those who received MSD-HSCT, and the better GvHD-free, relapse-free survival and the lower chronic GvHD than the patients in the MUD-HSCT group. These observations suggest that haplo-HSCT is a reasonable alternative with comparable efficacy if MSD-HSCT and MUD-HSCT cannot be performed. Nonetheless, the primary studies included in this meta-analysis were observational in nature, and randomized-controlled trials are still needed to confirm the efficacy of haplo-HSCT.

Keywords

haploidentical, stem cell, transplantation, conditioning regimen, acute myeloid leukemia

² Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Submitted: June 12, 2019. Revised: January 5, 2020. Accepted: January 15, 2020.

Corresponding Author:

Crea

BY NC

¹ Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Weerapat Owattanapanich, Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand. Email: weerapato36733@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Introduction

Because of the relatively poor survival outcomes of intermediate- and high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients, hematopoietic stem cell transplantation (HSCT) during first complete remission (CR1) is the first option for those aiming for a cure^{1–7}. A matched sibling donor (MSD) is the best option for HSCT due to the lower rates of nonrelapse mortality (NRM) and graft-versus-host disease (GvHD), which contribute to a higher rate of long-term survival. However, only 30% of patients have full MSDs⁸. Although a matched unrelated donor (MUD) is a good alternative, the higher expense and the long waiting duration involved in identifying matched donors are common obstacles⁹.

Haploidentical (haplo) HSCT is a novel technique that employs stem cell transplantation from first-degree relatives that have at least 5/10 to 8/10 matched human leukocyte antigen (HLA). This approach may help to increase the availability of first-degree relatives, although studies have shown that a higher rate of GvHD and graft rejection as well as a slower immune reconstitution are its major disadvantages^{10,11}. However, after the development of the two main methods, the Baltimore protocol (which applies post-transplantation cyclophosphamide to destroy alloreactive T cells)^{12,13} and the Beijing method (which uses granulocyte colony-stimulating factor prime bone marrow plus peripheral blood stem cells [PBSC] combined with a myeloablative conditioning [MAC] regimen and anti-thymocyte globulin to enhance rapid engraftment without increasing GvHD)^{14,15}, the aforementioned unfavorable events appear to occur less frequently. In fact, several comparative studies have suggested that haplo-HSCT has comparable outcomes to MSD-HSCT and MUD-HSCT^{16,17}. The current systematic review and meta-analysis was conducted with the aim of summarizing the study results in order to compare the efficacy and toxicity of MSD-HSCT and MUD-HSCT versus haplo-HSCT for patients with AML and MDS.

Materials and Methods

Data Sources and Searches

Articles published before September 15, 2018, were identified in two databases (MEDLINE and EMBASE) by two investigators (CK and WO). The search terms consisted of the terms for haploidentical transplantation, AML, and MDS (provided as supplemental data S1). References of the eligible articles and some review articles were also manually examined to identify additional eligible studies. This process was conducted independently by the two investigators. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, which was used as a guideline for this meta-analysis, is provided as supplemental data S2¹⁸.

Selection Criteria and Data Extraction

The inclusion criteria for this meta-analysis were as follows: (1) eligible studies must be randomized-controlled studies or cohort studies (either prospective or retrospective) that compared the efficacy of haplo-HSCT to any other stem cell sources for HSCT in AML or MDS; and (2) the studies must report the primary outcome of interest, which was the overall survival (OS) rate and/or leukemia-free survival (LFS) after HSCT. The secondary outcomes of interest (NRM, cumulative incidence of relapse [CIR], GvHD-free/relapse-free survival [GRFS], grade 2 to 4 acute GvHD, and chronic GvHD) were also extracted from the included studies for additional analyses, but they were not part of the inclusion criteria. This process was also independently performed by the two investigators. If different decisions regarding the eligibility were made, the studies in question were jointly discussed with a third investigator (PU), who served as a tiebreaker.

Data on the baseline characteristics of the included studies, along with the primary and secondary outcomes of interest, were extracted by the two investigators. This process was also conducted independently by the investigators, using a standard study record form. The extracted data were crosschecked to ensure their accuracy.

Outcome Definitions

The time between the stem cell infusion and the time of death or last follow-up was used for the calculation of the OS rate, while the time used for the calculation of the event-free survival rate was defined as the time interval from the stem cell infusion to the date of relapse, secondary malignancies, any infections after discharge from the bone marrow transplant unit, or death from any causes. LFS was defined as the time interval from the stem cell infusion to the stem cell infusion to the date of relapse or death from any causes. Relapse was estimated in those patients who achieved CR using a cumulative incidence function with respect to competing risks. The NRM rate included all causes of death except death from relapsed disease. GRFS was defined as patients with grade 2 to 4 acute GvHD, chronic GvHD requiring treatment, relapsed disease, or death.

Quality Assessment

The included randomized-controlled studies were assessed for their quality using the Jadad Quality Assessment Scale¹⁹. The Newcastle–Ottawa Scale was used to evaluate the quality of the included nonrandomized studies²⁰.

Statistical Analysis

The effect estimates and 95% confidence intervals (CIs) from each eligible study were combined using the Mantel–Haenszel method²¹. Cochran's Q was calculated, and statistical heterogeneity among the included studies was estimated using the I^2 statistic. The four levels of heterogeneity




Figure 1. The literature review and selection process. AML: acute myeloid leukemia; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation.

were based on the value of I^2 : (1) insignificant heterogeneity (I^2 -value of 0% to 25%); (2) low heterogeneity (I^2 -value of 26% to 50%); (3) moderate heterogeneity (I^2 -value of 51% to 75%); and (4) high heterogeneity (I^2 -value of 76% to 100%)²². Due to the high likelihood of between-study heterogeneity, a random-effects model was utilized rather than a fixed-effects model. Funnel plots were created to assess for publication bias. Statistical significance was determined to be P < 0.05. All statistical analyses were performed using Review Manager 5.3 software from the Cochrane Collaboration (London, UK).

Results

The aforementioned search strategy identified 1,646 potentially relevant articles (283 articles from MEDLINE and 1,363 from EMBASE). After exclusion of 261 duplicated articles, the titles and abstracts of the remaining 1,385 articles were reviewed. Of those, 1,348 were excluded for any one of the following reasons: (1) ineligible type of article (case report, review, meta-analysis, comments, and editorial); (2) the study was not on patients with AML or AML and MDS; (3) the study did not have a haplo-HSCT group versus an MSD-HSCT or MUD-HSCT group; and (4) the present study's primary outcome of interest was not reported. The remaining 37 articles underwent a full-length article review, and 23 were excluded at this point due to the same reasons as the first round. Finally, 14 studies (1 prospective cohort study and 13 retrospective cohort studies) met the eligibility criteria and were included in the meta-analysis^{15,23–35}. Figure 1 demonstrates the literature review and selection process.

Baseline Patient Characteristics

A total of 9,800 patients were included (1,106 patients with haplo-HSCT, 3,109 with MSD-HSCT, and 5,585 with MUD-HSCT), with a slight male predominance (around 1.2 to 1.4 as many males as females across the studies) and ages between 2 and 76 y^{15,23,25-29,31,33-35}. Majority of patients included in this cohort had AML (99.4%). Most studies categorized the AML disease into favorable, intermediate, and high risk by cytogenetic data, in accordance with the guidelines and recommendations of the National Comprehensive Cancer Network (NCCN)^{15,23,26,28,31}, UK Medical Research Council^{27,30}, the European LeukemiaNet, or the Southwest Oncology Group study^{24,30,33,34}. It should be noted that Ciurea et al. used the cytogenetic risk as recommended by the NCCN, but ≥ 4 complex chromosomes were used to define the high-risk category²⁹. Two studies defined the risk according to the NCCN guideline by using both cytogenetic and molecular abnormalities^{26,28}. The other 62 patients were high-risk MDS.

References	Group	Ň	Sex (M/ F)	Median age (years, range)	HCT-Cl or EBMT (0/1/2/3/4/5)	Diseases -Type of AML -CR status -Cytogenetic risk (fav/inter/high)	Conditioning regimen Donor source (MAC/RIC (PBSC/BM/ /non-MAC) PBSC+BM)		Median CD 34+ Study perio (×10 ⁶ cells/kg, range) median F/U	Study period/ median F/U	Туре	Quality assessment
Wang et al. ¹⁵	MSD	219	1 22/97	40 (17–60)	I	-CR1/2/3-4: 156/50/13 -Cytogenetic risk: 0/187/32 (NCCN by cytogenetics only)	219/0/0	81/14/124	2.2 (0.3–8.3)	July 2010–November Prospective 2013 cohort st	Prospective cohort study	.2 2 4 0 0 0 4
	Haplo	231	I 44/87	28 (15–57)	I	- CR1/2/3-4:155/60/16 -Cytogenetic risk: 0/183/ 48	231/0/0	0/0/ 231	2.5 (0.4–17.0)			
Chang et al. (retrospective) ²³	MSD	66	50/49	41 (12–57)	EBMT 0/26/57/12/3/1	-De novol secondary: 97/2 -CR1/>1: 93/5 -Cytogenetic risk: 17/78/4 (cytogenetics)	0/0/66	AN	2.3 (0.8–5.0)	January 2012–May 2014	Retrospective cohort study	.2 2 3 Ω 0 0 0
	Haplo	240	115/125	27 (2–60)	EBMT 0/47/99/64/22/8		240/0/0	0/0/240	2.3 (0.5–9.5)			
Chang et al. (prospective) ²³	MSD	82	47/35	39 (4–62)	EBMT 2/27/34/15/4/0	-Cytogeneuc risk: 42 102/13 -De novo/ secondary: 79/3 -CR1/>1: 71/ 11 -Cytogenetic risk: 8/66/8	82/0/0	AN	2.5 (0.4–6.4)	June 2014– December 2015	Prospective cohort study	
	Haplo	258	161/97	30 (3–65)	EBMT 0/39/111/76/26/6		258/0/0	0/0/258	2.5 (0.2–11.0)			
How et al. ²⁴	MSD	42	٩N	60 (32–72)	HCT-CI 0/1-2/≥3: 4/5/23	-De novo/secondary AML: 20/12	21/11/0	32/0/0	ΔN	2012–2015	Retrospective cohort study	ы С С С С С С С С
												ö
	Haplo	24	A	54 (21–73)	HCT-CI 0/I-2/≥3: I/2/21	-De novo/secondary AML: 17/7 -All active AML -Primary induction failure/relapse- refractory: 12/12 -Cytogenetic risk: 2/10/12	16/8/0	24/0/0	۲			
Devillier et al. ²⁵	MSD	31	AN	Υ	HCT-Cl <3/≥3: 3/ 4	-AML > 60 years -CR1/CR2/no CR: 21/6/4 -Cytogenetic risk: 2123/8	5/22/4	29/2/0	4.2 (1.2–11)	2011-2016	Retrospective cohort study	S: 3 0 0: 2 2 2
	Haplo	33	AN	AN	HCT-CI <3/≥3: 8/22	-AML > 60 years -CR1/CR2/no CR: 18/7/8 -Cytogenetic risk: 0/73/7	0/24/9	33/0/0	5.5 (2.5–16)			
Liu et al. ²⁶	MSD	43	22/21	<40/≥40: 12/31	I	-All high-risk AML, CR I *NCCN 2016	43/0/0	AN	2.7 (2.3–3.1)	January 2008–July 2015	Retrospective cohort study	v s C S
	Haplo	127	71/56	<40/≥40: 83/43	I	-All high-risk AML, CR I	127/0/0	0/0/127	2.7 (2.4–3.0)	August I, 2008 and June 30, 2015		O: 2

(continued)

Table 1. Characteristics and Participants of Studies that Compared Haplo-HSCT to MSD-HSCT.

(continued)
_
Table

References	Group	Š	Group No. Sex (M/F)	Median age (years, range)	HCT-CI or EBMT (0/1/2/3/4/5)	Diseases -Type of AML -CR status -Cytogenetic risk (Fav/inter/high)	Conditioning regimen Donor source (MAC/RIC (PBSC/BM/ /non-MAC) PBSC+BM)	Donor source (PBSC/BM/ PBSC+BM) (Median CD 34+ Study perio (×10 ⁶ cells/kg. range) median F/U	Study period/ median F/U	Туре а	Quality assessment
Salvatore et al. ²⁷	MSD		2,469 1,296/1,172	: 50 (18–75)		-AML, CRI Currentin Hick, 0/1000/501	1,302/11,67/0	1,996/473/0		2007 and 2015	Retrospective	4 ;; 7 ;
	Haplo		185 103/82	50 (18–74)		-Cytugeneut risk: W1000/301 -AML, CRI	93/92/0	93/92/0				0.2
Di Stasi et al. ³⁴	MSD	87	52/35	60 (24–76) 3 (0–12)	3 (0–12)	- Cytogenetic risk: 0/122/63 -CR 25	0/87/0	84/3/0	AN	January 2005–	Retrospective	S: O
	Haplo	32	16/16	52 (20–67) 1.5 (0–5)	1.5 (0–5)	-Active disease 62 -Cytogenetic risk: 7/38/38 -CR 19	0/32/0	1/31/0	٩N	September 2012	cohort study	7 7 0 C
Bashev et al ³⁵	. Сум	٦۶		(77–04) £A	Тоти	-Active disease 13 -Cytogenetic risk: 4/17/10 -AML (781 - 15	12/25/0	0/0/18	NA	2006-2015	Retrospective	۳ ن
					0-2: 15 ≥3: 22	-AML CC2 or CR3: 4 -Active disease: 4 -MDS-14					cohort study	5 7 7 Ö Ü
	Haplo	33	17/16	66 (60–75)	HCT-CI 0-2: I9 ≥3: I4	-AML CRI: 12 -AML CR2 or CR3: 3 -Active disease: 3 -MDS: 15	2/31/0	16/17/0	AN			
AML: acute mye Leukemia Net; † myeloablative cc O: outcome.	eloid leu fav: favo onditioni	kemia; rable; F ng; MSI	BM: bone n /U: follow-ı D: matched	narrow; C: corr up; Haplo: hapl sibling donor; N	patibility; CR1: first c oidentical; HCTCI: he JA: not applicable; NC	AML: acute myeloid leukemia; BM: bone marrow; C: compatibility; CR1: first complete remission; CR2: second complete remission; EBMT: European Society for Blood and Marrow Transplantation; ELN: European Leukemia Net; fav: favorable; F/U: follow-up; Haplo: haploidentical; HCTCI: hematopoietic cell transplantation-specific comorbidity index; HSCT: hematopoietic stem cell transplantation: inter: intermediate; MAC: myeloablative conditioning; MSD: matched sibling donor; NA: not applicable; NCCN: The National Comprehensive Cancer Network; PBSC: peripheral blood stem cells; RIC: reduced intensity conditioning; S: selection; O: outcome.	complete remission; EE pecific comorbidity ind e Cancer Network; PBS	8MT: European lex; HSCT: hen SC: peripheral b	Society for Blood natopoietic stem lood stem cells; R	l and Marrow Trans cell transplantation: JC: reduced intensity	plantation; ELN: F inter: intermedia r conditioning; S: s	European Ee; MAC: Telection;

				-	-	-						
References	Group	Z	Sex (M/ F)	Median age (years, range)	HCT-CI or EBMT (0/1/2/3/4/5)	Diseases -Type -CR status -Cytogenetic risk (Fav/inter/high) (Conditioning regimen (MAC/RIC/non-MAC)	Donor source (PBSC/BM/ PBC+BM)	Median CD 34+ (×10 ⁶ cells/kg, range)	Study period/median F/U	Туре	Quality assessment
Cho et al. ²⁸	MUD Haplo	46 23	29/17	Y Y Z Z	Y Y	-CRI/>CRI: 17/6 -Cytogenetic risk: 2/34/10 (cytogenetic and molecular by NCCN 2011) -CR1/>CR1:	32/14/0 N.A	33/13/0 23/0/0	4.5 (0.5–14.2) 6.5 (4.7–10.5)	August 2008–December 2010	Prospective cohort study	с; х С 2 2 Э
Rashidi et al. ³⁰ MUD Haplo	A MUD Haplo	88 52	A A Z Z	63 (26–74) 54 (19–73)	HTC-Cl 0-1/>1: 61/27 HTC-Cl 0-1/>1: 39/13	-Cytogenetic risk: 1/18/4 -CR 1/CR2/active: 43/9/36 -Cytogenetic risk: 1/46/40 -CR 1/CR2/active: 21/9/22 -Cytogenetic risk:	39/49/0 23/29/0	88/0/0 52/0/0	5.0 (1.9–16.7) 5.0 (2.4–6.2)	January 2010-August 2015	Retrospective cohort study	2 2 3 3 0 0 3 3
Sun et al. ³¹ How et al. ²⁴	MUD Maplo MUD	87 87 43	43/44 54/33	33.6 (19.3–55.6) 33 (18–55) 55 (23–73)	NA NA HCT-CI 0/1-2/≥3: 5/5/33	 3/32/16 -De novo AML, CR1 -Intermediate-risk cytogenetics (Cytogenetics) -De novo/secondary AML: -De novo/secondary AML: -All active AML -All active AML -Primary induction failure/relapse-refractory: 2/2/21 -Cytogenetic risk: 2/2/21 -D. Annorecondary AML 	877/0/0 877/0/0 34/9/0	49/37/0 0/0/87 42/1/0	A A A A A A A A A A A A A A A A A A A	2006–2013 2008–2012 2012–2015	Retrospective cohort study Retrospective cohort study	2 2 2 a 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Ciurea et al. ²⁹ MUD Haplo		1982	-1 1982 1046/936 192 98/94	(c/12) +c			1,245/737/0 104/88/0	30/162/0	a a a	2008–2012	Retrospective cohort study	4 2 2 4
Lorentino et al. ³²	MUD Haplo	555 74	A A N A	53 (18–76) 49 (18–72)	A A A A A	91/52/49 -Cytogenetic risk: 16/139/33 -AML CR1 -High-risk cytogenetic by ELN 2017	278/57 39/35	454/102 46/28/0	A A Z Z	January 2007–December 2015	Retrospective cohort study	⊙ 2 3 3 0.2 2

(continued)

Table 2. Characteristics and Participants of Studies that Compared Haplo-HSCT to MUD-HSCT.

References	Group	No.	Sex (M/ F)	Median age (years, range)	HCT-Cl or EBMT (0/1/2/3/4/5)	Diseases -Type -CR status -Cytogenetic risk (Favlinter/high)	Conditioning regimen (MAC/RIC/non-MAC)	Donor source (PBSC/BM/ PBC+BM)	Median CD 34+ (×10 ⁶ cells/kg, range)	Study period/median F/U	Туре	Quality assessment
Santoro et al. ³³	ΩŊ₩	2589	2589 I,471/I,I 14	64.8 (62.2–67.6)	٩	-AML ≥60 years -De novo/secondary AML: 508/902 -CR1/CR/active: 1,377/436/776 -cytogenetics risk: 77/210/21	591/1,948	2,422/167/0	Ϋ́	2001–2014	Retrospective cohort study	S: 4 0: 2 0: 2
	Haplo	250	156/94	65 (62.3–66.9) NA		(yougeneur nak vy ELN 2010) -De novo/secondary AML: 76/92 -CR1/CR/active: 95/46/109 -cytogenetics risk: 17/78/31	66/182	121/129/0	A	2006–2014		
Devillier et al. ²⁵	МИР	30	AN	AN	HCT-CI: 12/16	CR1/CR1active: 27/1/2 Cytogenetic risk: 3/15/13	5/25/0	20/1/0	6.7 (2.9–18)	2011–2016	Retrospective cohort study	3 U U U
	Haplo	33	AN	ЧA	HCT-CI: 8/22	AML >60 years CR1/CRVactive: 18/7/8 Cytogenetic: 0/23/7	0/24/9	33/0/0	5.5 (2.5–16)	A		
Di Stasi et al. ³⁴ MUD	MUD	108	60/48	62 (21–76)	HCT CI: 3 (0–9)	-CR 26 -Active disease 82 -Cytogenetic risk: 11/55/40	0/108/0	58/50/0	AN	January 2005–September Retrospective 2012 cohort stud	Retrospective cohort study	S C C S C S
	Haplo	32	16/16	52 (20–67)	HCT-CI: 1.5 (0–5)	-CR 19 -Active disease 13 -Cytogenetic risk: 4/17/10	0/32/0	1/31/0	AN			
Bashey et al. ³⁵ MUD	ДЛМ	57	36/21	65 (60–74)	HCT-CI: 0-2: 24 ≥3: 33	-AML CR1 : 19 -AML CR2 or CR3:7 -Active disease: 8 -MDS: 23	17/40/0	45/12/0	Υ	2006–2015	Retrospective cohort study	ы с 2 с С С 2 а
	Haplo	33	17/16	66 (60–75)	HCT-CI: 0-2: 19 ≥3: 14	-AML CR1 12: -AML CR2 or CR3:3 -Active disease: 3 -MDS: 15	2/31/0	16/17/0	A			

AML: acute myeloid leukemia; BM: bone marrow; C: compatibility; CR1: first complete remission; CR2: second complete remission; DRI: disease risk index; EBMT: European Society for Blood and Marrow Transplantation; fav: favorable; F/U: follow-up; Haplo:-haploidentical: HCTCI: hematopoietic cell transplantation-specific comorbidity index; HSCT: hematopoietic stem cell transplantation, inter: intermediate; MAC: myeloablative conditioning; MUD: matched unrelated donor; MDS: myelodysplastic syndrome; NA: not applicable; NCCN: The National Comprehensive Cancer Network; PBSC: peripheral blood stem cells; RIC: reduced intensity conditioning; S: selection; O: outcome.

Table 2. (continued)

Α		Hapl	0	MS)		Odds Ratio		Odds Ratio
<u> </u>	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
	Wang 2015	182	231	180	219	18.2%	0.80 [0.50, 1.29]	2015	
	How 2017	9	24	9	32	3.1%	1.53 [0.50, 4.75]	2017	
	Chang 2017	384	498	140	181	24.2%	0.99 [0.66, 1.48]	2017	
	Bashey 2018	22	33	23	37	4.1%	1.22 [0.46, 3.25]	2018	
	Salvatore 2018	126	185	1876	2469	38.4%	0.68 [0.49, 0.93]	2018	
	Liu 2018	81	127	27	43	7.8%	1.04 [0.51, 2.14]	2018	
	Devillier 2018	18	33	16	31	4.1%	1.13 [0.42, 3.01]	2018	
	Total (95% CI)		1131		3012	100.0%	0.85 [0.70, 1.04]		•
	Total events	822		2271					
	Heterogeneity: Tau ² =	0.00; Chi	² = 4.7	2, df = 6 (P = 0.5	8); l² = 09	6		
	Test for overall effect:	Z=1.61 (P = 0.1	1)					
									MSD more OS Haplo more OS
в		Hapl	0	MS)		Odds Ratio		Odds Ratio
-	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% CI
	Di Stasi 2014	10	32	31	87	6.4%	0.82 [0.35, 1.95]	2014	· · · · · · · · · · · · · · · · · · ·
	Wang 2015	171	231	171	219	19.7%	0.80 [0.52, 1.24]	2015	
	Chang 2017	368	498	132	181	23.3%	1.05 [0.72, 1.54]	2017	_
	Devillier 2018	17	33	15	31	5.1%	1.13 [0.42, 3.02]	2018	
	Bashey 2018	19	33	19	37	5.5%	1.29 [0.50, 3.31]	2018	
	Salvatore 2018	107	185	1654	2469	30.7%	0.68 [0.50, 0.92]	2018	
	Liu 2018	80	127	22	43	9.4%	1.62 [0.81, 3.27]	2018	
			1139		3067	100.0%	0.91 [0.72, 1.14]		•
1	Total (95% CI)		1128		0001				
	Total (95% CI) Total events	772	1159	2044					
						6); I² = 23	%		
	Total events	0.02; Chi	² = 7.7	6, df = 6 (6); I² = 23	%		0.2 0.5 1 2 5 MSD more LFS Haplo more LFS

Figure 2. Forest plots of studies that compared (A) overall survival and (B) leukemia-free survival among patients who underwent haplo-HSCT versus MSD-HSCT.

CI: confidence interval; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; LFS: leukemia-free survival; MSD: matched sibling donor; OS: overall survival.

The majority of patients in all three groups were in CR1 and had intermediate- to high-risk cytogenetics. In all, 78% of patients in the MSD-HSCT group and 88% in the MUD-HSCT group received PBSC, while 78% in the haplo-HSCT group received bone marrow plus PBSC. The characteristics of the studies that compared MSD-HSCT to haplo-HSCT are described in Table 1, whereas the characteristics of the studies that compared MUD-HSCT to haplo-HSCT are presented in Table 2. Supplemental Tables S1 and S2 detail the conditioning regimen and GvHD prophylaxis of the studies that compared MUD-HSCT to haplo-HSCT, and of the studies that compared MUD-HSCT to haplo-HSCT, respectively.

Comparison of Outcomes of Haplo-HSCT Versus MSD-HSCT

Long-term outcomes, including OS, LFS, NRM, and CIR, were reported in six studies (a 2-y follow-up in four studies, a 3-y follow-up in three studies, and a 4-y follow-up in one study). The OS rate was not significantly different between the groups, with a pooled odds ratio (OR) of the chance of surviving at the end of the study when comparing haplo-HSCT to MSD-HSCT of 0.85 (95% CI: 0.70 to 1.04; P = 0.11; $I^2 = 0\%$; Fig. 2A)^{15,23-27,35}. Similarly, the chance of achieving LFS was not significantly different between the

groups (pooled OR: 0.91; 95% CI: 0.72 to 1.14; P = 0.40; $I^2 = 23\%$; Fig. 2B)^{15,23,25-27,34,35}. The chance of developing NRM was also similar between the two groups (pooled OR: 1.37; 95% CI: 0.88 to 2.12; P = 0.16; $I^2 = 62\%$; Fig. 3A)^{15,23–27,34}. Likewise, CIR was insignificantly lower in the haplo-HSCT group, with a pooled OR for developing at least one relapse of 0.80 (95% CI: 0.64 to 1.00; P = 0.05; $I^2 = 0\%$; Fig. 3B) compared with those who received MSD-HSCT^{15,23,25-27,34,35}. The GRFS was also not different between the two groups (pooled OR: 0.88; 95% CI: 0.66 to 1.17; P = 0.38; $I^2 = 0\%$; Fig. 3C)^{25,27}. For the analyses of the adverse effects, the patients who received haplo-HSCT had a significantly higher chance of developing grade 2 to 4 acute GvHD than patients who received MSD-HSCT (pooled OR: 2.32; 95% CI: 1.52 to 3.56; P < 0.0001; $I^2 = 67\%$; Fig. 4A)^{15,23-27,34,35}. The chance of developing chronic GvHD was similar for the two groups (pooled OR: 0.98; 95% CI: 0.53 to 1.82; P = 0.96; $I^2 = 86\%$; Fig. 4B)^{15,23–25,27,34,35}.

Comparative Outcomes Between Haplo-HSCT and MUD-HSCT

Long-term outcomes, including OS, LFS, NRM, and CIR, were reported in eight studies (a 1.5-y follow-up in one

		Hank		MSE			Odds Ratio			Odds Ratio	
Α	Study or Subgroup	Haple				Moight	M-H, Random, 95% Cl	Voor		M-H, Random, 95% Cl	
8.										M-H, Raildoni, 95% Cl	_
	Di Stasi 2014	8	32	17	87	11.6%	1.37 [0.53, 3.58]				
	Wang 2015	30	231	18	219	17.1%	1.67 [0.90, 3.09]				
	How 2017	6	24	13	32	9.2%	0.49 [0.15, 1.56]				
	Chang 2017	70	498	21	181	19.0%	1.25 [0.74, 2.10]				
	Salvatore 2018	43	185		2469	21.9%	2.72 [1.89, 3.93]				
	Devillier 2018	8	33	6	31	8.9%	1.33 [0.40, 4.40]				
	Liu 2018	19	127	8	43	12.3%	0.77 [0.31, 1.91]	2018			
	Total (95% CI)		1130		3062	100.0%	1.37 [0.88, 2.12]			◆	
	Total events	184		330							
	Heterogeneity: Tau ² =	0.19; Chi	² = 15.8	9, df = 6	(P = 0.1)	02); I ² = 6	2%		0.05	0.2 1 5 20	
	Test for overall effect:	Z=1.40 (P = 0.1	6)					0.05	0.2 1 5 20	
										MSD more NRM Haplo more NRM	
в		Heat		MS			Odds Ratio			Odds Ratio	
	Study or Subaroup	Haple				Maight		Veer			
	Study or Subgroup	221 x 1 7 27		10.000			M-H, Random, 95% CI	1		M-H, Random, 95% Cl	_
	Di Stasi 2014	11	32	24	87	6.9%	1.38 [0.58, 3.27]				
	Wang 2015	35	231	33	219	19.5%	1.01 [0.60, 1.69]				
	Chang 2017	59	498	28	181	22.0%	0.73 [0.45, 1.19]				
	Bashey 2018	3	33	6	37	2.4%	0.52 [0.12, 2.26]		•		
	Devillier 2018	8	33	10	31	4.3%	0.67 [0.22, 2.01]			-	
	Salvatore 2018	35	185	593		36.1%	0.74 [0.51, 1.08]				
	Liu 2018	28	127	13	43	8.7%	0.65 [0.30, 1.42]	2018			
	Total (95% CI)		1139		3067	100.0%	0.80 [0.64, 1.00]			•	
	Total events	179		707						2000 - 20000 - 2000 - 2000 - 2000 - 2000 - 2000 - 2000 - 2000 - 2000 - 2	
	Heterogeneity: Tau ² =	0.00; Chi	² = 3.25	5, df = 6 (P = 0.7	8); I² = 09	6		0.2		
	Test for overall effect:	Z=1.93 (P = 0.0	5)					0.2		
										MSD more CIR Haplo more CIR	
С		Hap	olo	м	SD		Odds Ratio			Odds Ratio	
•	Study or Subgroup	Events	Tota	I Event	s Tot	al Weig	ht M-H, Random, 959	% CI		M-H, Random, 95% Cl	
	Devillier 2018	11	33	3 1	2 3	1 7.9	0.79 [0.28, 2	.20]			
	Salvatore 2018	87	18	5 123	4 248	9 92.1	% 0.89 [0.66, 1	.20]			
	Total (95% CI)		21	3	250	0 100.0	0.88 [0.66, 1	.17]		•	
	Total events	98	3	124	6						
	Heterogeneity: Tau ² :	= 0.00; CI	hi² = 0.	05, df = 1	1 (P = ().83); l² =	0%	-	-1-		_
	Test for overall effect				,				0.05	0.2 1 5 20	
			·. ·	-,						MSD more GRFS Haplo more GRFS	
										ana na sanananana sa sa bahar na na sa	

Figure 3. Forest plots of studies that compared (A) nonrelapse mortality; (B) cumulative incidence of relapse and (C) GRFS among patients who underwent haplo-HSCT versus MSD-HSCT.

Cl: confidence interval; ClR: cumulative incidence of relapse; GRFS: graft-versus-host-disease-free/relapse-free survival; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; MSD: matched sibling donor; M-H: Mantel-Haenszel Method; NRM: nonrelapse mortality.

study; a 2-y follow-up in five studies; a 3-y follow-up in three studies; and a 5-y follow-up in one study)^{24,25,28–35}. The OS rate was not significantly different between the groups, with a pooled OR comparing the chance of surviving at the end of the study when comparing haplo-HSCT to MUD-HSCT of 1.12 (95% CI: 0.89 to 1.41; P = 0.35; $I^2 = 33\%$; Fig. 5A)^{24,25,28–33,35}. Similarly, the chance of achieving LFS was not significantly different between the groups (pooled OR: 1.21; 95% CI: 0.87 to 1.68; P = 0.26; $I^2 = 46\%$; Fig. 5B)^{25,28,31–35}. The chance of developing NRM was also similar between the two groups (pooled OR: 0.85; 95% CI: 0.55 to 1.32; P = 0.47; $I^2 = 65\%$; Fig. 6A)^{24,25,28–31,33,34}, the same as the chance of developing CIR (pooled OR: 0.91; 95% CI: 0.65 to 1.27; P = 0.59; $I^2 = 61\%$; Fig. 6B)^{25,28–34}. However, the GRFS was

significantly better in haplo-HSCT group (pooled OR: 1.40; 95% CI: 1.10 to 1.78; P = 0.007; $I^2 = 0\%$; Fig. 6C)^{25,27,32}. The chance of developing grade 2 to 4 acute GvHD was not different between two groups (pooled OR: 0.82; 95% CI: 0.65 to 1.03; P = 0.09; $I^2 = 29\%$; Fig. 7A)^{24,25,28–35}; in contrast, the patients in the haplo-HSCT group had a significantly lower chance of developing chronic GvHD than those in the MUD-HSCT group (pooled OR: 0.59; 95% CI: 0.48 to 0.73; P < 0.00001; $I^2 = 15\%$; Fig. 7B)^{24,25,28–35}.

Sensitivity Analysis

A sensitivity analysis was conducted by excluding the studies by Wang et al.¹⁵, Chang et al.²³, and Liu et al.²⁶ from the

Α		Hapl	0	MSD)		Odds Ratio		Odds Ratio
~	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl A
	Di Stasi 2014	9	32	27	87	11.0%	0.87 [0.36, 2.13]	2014	
	Wang 2015	83	231	28	219	16.8%	3.83 [2.37, 6.18]	2015	
	How 2017	14	24	12	32	9.0%	2.33 [0.79, 6.88]	2017	
	Chang 2017	165	498	16	181	15.8%	5.11 [2.96, 8.82]	2017	
	Liu 2018	56	127	12	43	12.8%	2.04 [0.96, 4.33]	2018	
	Bashey 2018	13	33	10	37	9.7%	1.75 [0.64, 4.80]	2018	
	Salvatore 2018	57	185	518	2469	18.9%	1.68 [1.21, 2.33]	2018	
	Devillier 2018	7	33	3	31	6.1%	2.51 [0.59, 10.76]	2018	
	Total (95% CI)		1163		3099	100.0%	2.32 [1.52, 3.56]		•
	Total events	404		626					
	Heterogeneity: Tau ² =	0.22; Chi	= 21.3	38, df = 7	(P = 0.1)	003); I ^z =	67%		0.05 0.2 1 5 20
	Test for overall effect:	Z = 3.87 (P = 0.0	001)					
									MSD more aGVHD Haplo more aGVHD
P		Hanl	0	MSE			Odde Patio		Odds Patio
В	Study or Subaroup	Hapl		MSE		Weight	Odds Ratio	Vear	Odds Ratio M-H Random 95% Cl
В	Study or Subgroup	Events	Total	Events	Total		M-H, Random, 95% Cl		
В	Di Stasi 2014	Events 6	Total 32	Events 37	Total 87	12.9%	M-H, Random, 95% Cl 0.31 [0.12, 0.83]	2014	
В	Di Stasi 2014 Wang 2015	Events 6 97	Total 32 231	Events 37 33	Total 87 219	12.9% 17.4%	M-H, Random, 95% CI 0.31 [0.12, 0.83] 4.08 [2.59, 6.42]	2014 2015	
В	Di Stasi 2014 Wang 2015 How 2017	Events 6 97 3	Total 32 231 24	Events 37 33 5	Total 87 219 32	12.9% 17.4% 8.7%	M-H, Random, 95% CI 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60]	2014 2015 2017	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017	Events 6 97 3 249	Total 32 231 24 498	Events 37 33 5 101	Total 87 219 32 181	12.9% 17.4% 8.7% 18.1%	M-H, Random, 95% CI 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60] 0.79 [0.56, 1.11]	2014 2015 2017 2017	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018	Events 6 97 3 249 8	Total 32 231 24 498 33	Events 37 33 5 101 8	Total 87 219 32 181 31	12.9% 17.4% 8.7% 18.1% 11.6%	M-H, Random, 95% Cl 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60] 0.79 [0.56, 1.11] 0.92 [0.30, 2.85]	2014 2015 2017 2017 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017	Events 6 97 3 249	Total 32 231 24 498	Events 37 33 5 101	Total 87 219 32 181	12.9% 17.4% 8.7% 18.1%	M-H, Random, 95% CI 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60] 0.79 [0.56, 1.11]	2014 2015 2017 2017 2018 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018 Santoro 2018 Bashey 2018	Events 6 97 3 249 8 61	Total 32 231 24 498 33 185 33	Events 37 33 5 101 8 864	Total 87 219 32 181 31 2469 37	12.9% 17.4% 8.7% 18.1% 11.6% 18.2% 13.1%	M-H, Random, 95% Cl 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60] 0.79 [0.56, 1.11] 0.92 [0.30, 2.85] 0.91 [0.67, 1.26] 0.85 [0.33, 2.22]	2014 2015 2017 2017 2018 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018 Santoro 2018 Bashey 2018 Total (95% CI)	Events 6 97 3 249 8 61 13	Total 32 231 24 498 33 185	Events 37 33 5 101 8 864 16	Total 87 219 32 181 31 2469 37	12.9% 17.4% 8.7% 18.1% 11.6% 18.2%	M-H, Random, 95% CI 0.31 [0.12, 0.83] 4.08 [2.59, 6.42] 0.77 [0.17, 3.60] 0.79 [0.56, 1.11] 0.92 [0.30, 2.85] 0.91 [0.67, 1.26]	2014 2015 2017 2017 2018 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018 Santoro 2018 Bashey 2018 Total (95% CI) Total events	Events 6 97 3 249 8 61 13 437	Total 32 231 24 498 33 185 33 185 33 1036	Events 37 33 5 101 8 864 16 1064	Total 87 219 32 181 31 2469 37 3056	12.9% 17.4% 8.7% 18.1% 11.6% 18.2% 13.1% 100.0%	M-H, Random, 95% CI 0.31 (0.12, 0.83) 4.08 (2.59, 6.42) 0.77 (0.17, 3.60) 0.79 (0.56, 1.11) 0.92 (0.30, 2.85) 0.91 (0.67, 1.26) 0.85 (0.33, 2.22) 0.98 [0.53, 1.82]	2014 2015 2017 2017 2018 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018 Santoro 2018 Bashey 2018 Total (95% CI) Total events Heterogeneity: Tau ² =	Events 6 97 3 249 8 61 13 437 0.51; Ch	Total 32 231 24 498 33 185 33 1036 F = 43.9	Events 37 33 5 101 8 864 16 1064 91, df = 6	Total 87 219 32 181 31 2469 37 3056	12.9% 17.4% 8.7% 18.1% 11.6% 18.2% 13.1% 100.0%	M-H, Random, 95% CI 0.31 (0.12, 0.83) 4.08 (2.59, 6.42) 0.77 (0.17, 3.60) 0.79 (0.56, 1.11) 0.92 (0.30, 2.85) 0.91 (0.67, 1.26) 0.85 (0.33, 2.22) 0.98 [0.53, 1.82]	2014 2015 2017 2017 2018 2018	
В	Di Stasi 2014 Wang 2015 How 2017 Chang 2017 Devillier 2018 Santoro 2018 Bashey 2018 Total (95% CI) Total events	Events 6 97 3 249 8 61 13 437 0.51; Ch	Total 32 231 24 498 33 185 33 1036 F = 43.9	Events 37 33 5 101 8 864 16 1064 91, df = 6	Total 87 219 32 181 31 2469 37 3056	12.9% 17.4% 8.7% 18.1% 11.6% 18.2% 13.1% 100.0%	M-H, Random, 95% CI 0.31 (0.12, 0.83) 4.08 (2.59, 6.42) 0.77 (0.17, 3.60) 0.79 (0.56, 1.11) 0.92 (0.30, 2.85) 0.91 (0.67, 1.26) 0.85 (0.33, 2.22) 0.98 [0.53, 1.82]	2014 2015 2017 2017 2018 2018	M-H, Random, 95% CI

Figure 4. Forest plots of studies that compared (A) acute GvHD and (B) chronic GvHD among patients who underwent haplo-HSCT versus MSD-HSCT.

CI: confidence interval; GvHD: graft-versus-host disease; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; M-H: Mantel-Haenszel Method; MSD: matched sibling donor.

full analysis (two studies were excluded at a time). This sensitivity analysis was conducted because of a concern that some patients may have been recruited to more than one of the three studies (the three studies were conducted at the same institute during the overlapping period of time), resulting in double-counting of the same patients. We found that the results of most analyses were not significantly different from the full analysis, either with the exclusion of the study by Wang et al.¹⁵, Chang et al.²³, or Liu et al.²⁶ except:

- 1. the LFS outcome for the haplo-HSCT versus MSD-HSCT analysis became significant when studies by Chang et al.²³ and Liu et al.²⁶ were excluded. The new analysis found that the chance of achieving LFS for patients who received haplo-HSCT was significantly lower than for patients who received MSD-HSCT (new pooled OR: 0.76; 95% CI: 0.61 to 0.96; P = 0.02; $I^2 = 0\%$).
- 2. the CIR outcome for the haplo-HSCT versus MSD-HSCT analysis became insignificant when studies by Chang et al.²³ and Liu et al.²⁶ were excluded, with the new pooled OR comparing haplo-HSCT to MSD-HSCT of 0.84 (95% CI: 0.64 to 1.11; P = 0.22; $I^2 = 0\%$).

Subgroup Analysis

We selected data, which included only patients with CR prior to HSCT and reanalyzed the primary outcome. The pooled OS and LFS for haplo-HSCT versus MSD-HSCT analysis were not different from the full analysis. Similarly, the pooled OS and LFS for haplo-HSCT versus MUD-HSCT analysis were not different from the full analysis (supplemental data S3A).

Because post-transplant cyclophosphamide is now widely used for GvHD prophylaxis especially in patients with haploidentical transplantation³⁶, we selected data that included only patients who received this GvHD prophylaxis protocol and reanalyzed the acute and chronic GvHD outcomes. The pooled acute and chronic GvHD for haplo-HSCT versus MSD-HSCT analysis and haplo-HSCT versus MUD-HSCT were not different from the full analysis (supplemental data S3B).

Evaluation of Publication Bias

Funnel plots of the primary outcome analysis (OS) were constructed for both haplo-HSCT versus MSD-HSCT and haplo-HSCT versus MUD-HSCT comparisons (supplemental data S4). The plots were relatively symmetric, which was not suggestive of the presence of publication bias.

		Hapl	0	MUE)		Odds Ratio		Odds Ratio
_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
	Cho 2012	15	23	34	43	3.8%	0.50 [0.16, 1.54]	2012	• • •
	Ciurea 2015	87	192	947	1982	23.7%	0.91 [0.67, 1.22]	2015	
	Rashidi 2016	22	52	33	88	8.6%	1.22 [0.61, 2.46]	2016	
	How 2017	9	24	12	43	4.3%	1.55 [0.54, 4.48]	2017	
	Lorentino 2018	44	74	279	556	14.1%	1.46 [0.89, 2.38]		
	Bashey 2018	22	33	31	57	5.8%	1.68 [0.69, 4.09]	2018	
	Sun 2018	68	87	55	87	9.2%	2.08 [1.07, 4.07]	2018	
	Santoro 2018	97	250	1087	2589	25.7%	0.88 [0.67, 1.14]	2018	
	Devillier 2018	18	33	15	30	4.8%	1.20 [0.45, 3.23]	2018	
	Total (95% CI)		768		5475	100.0%	1.12 [0.89, 1.41]		•
	Total events	382		2493					
	Heterogeneity: Tau ² =	0.04; Chi	² = 11.9	92, df = 8	(P = 0.	15); I ² = 3	3%		0.2 0.5 1 2
	Test for overall effect:	2 - 0.33 (r = 0.3	.5)					MUD more OS Haplo more OS
	Testion overall ellect.				1		Odds Ratio		
		Hapl	0	MU		Weight	Odds Ratio M-H. Random, 95% CI	Year	Odds Ratio
	Study or Subgroup	Hapl Events	o Total	MUI	Total		M-H, Random, 95% Cl		
	Study or Subgroup Cho 2012	Hapl Events 15	o <u>Total</u> 23	MUI Events 31	Total 43	7.3%	M-H, Random, 95% Cl 0.73 [0.24, 2.15]	2012	Odds Ratio
	<u>Study or Subgroup</u> Cho 2012 Di Stasi 2014	Hapl Events	o Total	MUI	Total		M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93]	2012 2014	Odds Ratio
	Study or Subgroup Cho 2012	Hapl Events 15 10	o <u>Total</u> 23 32	MUI Events 31 29	Total 43 108	7.3% 10.4%	M-H, Random, 95% Cl 0.73 [0.24, 2.15]	2012 2014 2018	Odds Ratio
	<u>Study or Subgroup</u> Cho 2012 Di Stasi 2014 Devillier 2018	Hapl Events 15 10 17	o <u>Total</u> 23 32 33	MUI Events 31 29 14	Total 43 108 30	7.3% 10.4% 8.5%	M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27]	2012 2014 2018 2018	Odds Ratio
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018	Hapl Events 15 10 17 64	o Total 23 32 33 87	MUI Events 31 29 14 52	Total 43 108 30 87	7.3% 10.4% 8.5% 15.1%	M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55]	2012 2014 2018 2018 2018 2018	Odds Ratio
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018 Lorentino 2018	Hapl Events 15 10 17 64 39	0 <u>Total</u> 23 32 33 87 74	MUI Events 31 29 14 52 235	Total 43 108 30 87 556	7.3% 10.4% 8.5% 15.1% 20.0%	M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55] 1.52 [0.94, 2.48]	2012 2014 2018 2018 2018 2018 2018	Odds Ratio
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018 Lorentino 2018 Santoro 2018	Hapl Events 15 10 17 64 39 87	0 <u>Total</u> 23 32 33 87 74 250	MUI Events 31 29 14 52 235 1033	Total 43 108 30 87 556 2589 57	7.3% 10.4% 8.5% 15.1% 20.0% 28.4%	M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55] 1.52 [0.94, 2.48] 0.80 [0.61, 1.06]	2012 2014 2018 2018 2018 2018 2018	Odds Ratio
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018 Lorentino 2018 Santoro 2018 Bashey 2018	Hapl Events 15 10 17 64 39 87	0 <u>Total</u> 23 32 33 87 74 250 33	MUI Events 31 29 14 52 235 1033	Total 43 108 30 87 556 2589 57	7.3% 10.4% 8.5% 15.1% 20.0% 28.4% 10.3%	M-H, Random, 95% Cl 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55] 1.52 [0.94, 2.48] 0.80 [0.61, 1.06] 1.74 [0.73, 4.13]	2012 2014 2018 2018 2018 2018 2018	Odds Ratio
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018 Lorentino 2018 Santoro 2018 Bashey 2018 Total (95% CI)	Hapl Events 15 10 17 64 39 87 19 251	o Total 23 32 33 87 74 250 33 33 532	MUI Events 31 29 14 52 235 1033 25 1419	Total 43 108 30 87 556 2589 57 3470	7.3% 10.4% 8.5% 15.1% 20.0% 28.4% 10.3% 100.0%	M-H, Random, 95% CI 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55] 1.52 [0.94, 2.48] 0.80 [0.61, 1.06] 1.74 [0.73, 4.13] 1.21 [0.87, 1.68]	2012 2014 2018 2018 2018 2018 2018	Odds Ratio M-H, Random, 95% CI
	Study or Subgroup Cho 2012 Di Stasi 2014 Devillier 2018 Sun 2018 Lorentino 2018 Santoro 2018 Bashey 2018 Total (95% CI) Total events	Hapl Events 15 10 17 64 39 87 19 251 : 0.08; Chi	0 <u>Total</u> 23 32 33 87 74 250 33 532 ² = 11.1	MUI Events 31 29 14 52 235 1033 25 1419 04, df = 6	Total 43 108 30 87 556 2589 57 3470	7.3% 10.4% 8.5% 15.1% 20.0% 28.4% 10.3% 100.0%	M-H, Random, 95% CI 0.73 [0.24, 2.15] 1.24 [0.52, 2.93] 1.21 [0.45, 3.27] 1.87 [0.99, 3.55] 1.52 [0.94, 2.48] 0.80 [0.61, 1.06] 1.74 [0.73, 4.13] 1.21 [0.87, 1.68]	2012 2014 2018 2018 2018 2018 2018	Odds Ratio

Figure 5. Forest plots of studies that compared (A) OS and (B) LFS among patients who underwent haplo-HSCT versus MUD-HSCT. Cl: confidence interval; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; LFS: leukemia-free survival; M-H: Mantel-Haenszel Method; MUD: matched unrelated donor; OS: overall survival.

Discussion

Currently, there are three methods of GvHD prophylaxis in haplo-HSCT including post-transplant cyclophosphamide, antithymocyte globulin³⁶, and alpha-beta T cell deplete³⁷. However, this meta-analysis included only the first two methods. This is the first systematic review and metaanalysis to summarize all available studies that compared the efficacy and complications of haplo-HSCT with the standard HSCT (MSD-HSCT and MUD-HSCT) for patients with AML and MDS. The patient characteristics of MSD versus haplo-HSCT were comparable in terms of their age and sex distribution. The haplo group included more cases of active AML disease and AML in the second CR than the MSD arm. However, the MSD arm had about 10% more intermediateto high-risk cytogenetic patients than the haplo group. As around 80% of the patients in the haplo arm were from China, which uses the Beijing protocol, a higher proportion of patients in this arm received the MAC regimen and bone marrow plus PBSCs; conversely, a higher proportion in the MSD group received PBSCs.

In the comparison of MUD and haplo-HSCT, patients had comparable ages, sex, distributions of cytogenetic risk, and proportions receiving the MAC and RIC regimens. Similar to the former comparison, the haplo-HSCT group had a higher proportion of AML in the second CR and active diseases. Moreover, the MUD group used PBSCs at a higher ratio than the haplo-HSCT patients did.

The pooled analysis found that the chance of survival at the end of the study, which ranged from 1.5 to 5 y, of patients who underwent haplo-HSCT was not significantly different from patients who underwent either MSD-HSCT or MUD-HSCT. In addition, analyses of the secondary outcomes showed comparable results for haplo-HSCT and conventional HSCTs, except for the higher grade 2 to 4 acute GvHD among patients who received haplo-HSCT than those who received MSD-HSCT, and the lower chronic GvHD and better GRFS than patients in the MUD-HSCT group. These observations suggest that haplo-HSCT is a reasonable alternative with comparable efficacy if MSD-HSCT and MUD-HSCT cannot be performed. The significantly better GRFS in the haplo-HSCT group is probably an unintended benefit of a higher degree of HLA disparity of this approach, which introduces a higher immunogenicity³⁸. However, after excluding the three studies that might contain duplicated

		Hapl	0	MUD)		Odds Ratio		Odds Ratio
۰.	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
	Cho 2012	2	23	4	43	4.8%	0.93 [0.16, 5.50]	2012	
	Di Stasi 2014	8	32	38	108	11.7%	0.61 [0.25, 1.50]	2014	
	Ciurea 2015	23	192	419	1982	18.6%	0.51 [0.32, 0.80]	2015	
	Rashidi 2016	14	52	24	88	13.4%	0.98 [0.45, 2.13]	2016	
	How 2017	6	24	12	43	9.0%	0.86 [0.28, 2.69]	2017	
	Santoro 2018	94	250	730	2589	21.3%	1.53 [1.17, 2.01]	2018	
	Sun 2018	12	87	14	87	12.5%	0.83 [0.36, 1.92]	2018	
	Devillier 2018	7	33	8	30	8.7%	0.74 [0.23, 2.37]		
	Total (95% CI)		693		4970	100.0%	0.85 [0.55, 1.32]		•
	Total events	166		1249					
	Heterogeneity: Tau ² =		² = 20.0		(P = 0.1)	005); ² = 6	5%		
	Test for overall effect:								0.05 0.2 i 5 20
				.,					MUD more NRM Haplo more NRM
3		Hapl	0	MUE)		Odds Ratio		Odds Ratio
۰.	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
	Cho 2012	6	23	10	43	6.0%	1.16 [0.36, 3.75]	2012	· · · · · · · · · · · · · · · · · · ·
	Di Stasi 2014	11	32	25	108	9.1%	1.74 [0.74, 4.09]	2014	
	Ciurea 2015	97	192	796	1982	19.1%	1.52 [1.13, 2.05]	2015	
	Rashidi 2016	15	52	38	88	10.8%	0.53 [0.26, 1.11]	2016	
	Sun 2018	11	87	21	87	9.8%	0.45 [0.20, 1.01]	2018	
	Lorentino 2018	29	74	206	556	15.0%	1.09 [0.67, 1.80]		
	Devillier 2018	8	33	8	30	6.2%	0.88 [0.28, 2.74]		
	Bashey 2018	3	33	13	57	4.9%	0.34 [0.09, 1.29]		· · · · · · · · · · · · · · · · · · ·
	Santoro 2018	69	250	826	2589	19.3%	0.81 [0.61, 1.09]		
	Total (95% CI)		776		5540	100.0%	0.91 [0.65, 1.27]		•
	Total events	249		1943					
	Heterogeneity: Tau ² =	0.13; Ch	i ² = 20.5	53. df = 8	(P = 0.	008); l² = 6	i1%		
	Test for overall effect:	Z=0.54	(P = 0.5)	9)					0.1 0.2 0.5 1 2 5 10
			•						MUD more CIR Haplo more CIR
		Ha	olo	м	UD		Odds Ratio		Odds Ratio
,	Study or Subgroup					al Weigh	nt M-H, Random, 95	% CI	M-H, Random, 95% CI
	Devillier 2018	11				0 4.79			
	Lorentino 2018	30	7.	1 16	7 55	6 23.49			↓
	Santoro 2018	76	6 250		2 258				⊢ ∎−
	Total (95% CI)		35	7	317	5 100.0	% 1.40 [1.10, 1	.78]	•
	Total events	113		81					•
	Heterogeneity: Tau ²				-	1 701 12 - 1	n%.	-	
	Test for overall effect				20-0).(3),1 = 1	5.40	0	.1 0.2 0.5 1 2 5 1

Figure 6. Forest plots of studies that compared (A) nonrelapse mortality; (B) cumulative incidence of relapse and (C) GRFS among patients who underwent haplo-HSCT versus MUD-HSCT.

CI: confidence interval; CIR: cumulative incidence of relapse; GRFS: graft-versus-host-disease-free/relapse-free survival; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; M-H: Mantel-Haenszel Method; MUD: matched unrelated donor; NRM: nonrelapse mortality.

cases, a sensitivity analysis revealed that patients who received MSD-HSCT had significantly better LFS outcome than those with haplo-HSCT. We therefore believe that MSD-HSCT remains the first donor's choice for AML and MDS patients.

Nonetheless, the current systematic review and metaanalysis study has several limitations that may jeopardize the validity of the results. The most importation limitation was the observational nature of the included studies, as none were randomized-controlled studies. Therefore, it is very likely that the baseline characteristics of the patients in each group were not perfectly similar, and the observed results could therefore be skewed by the unequal distribution of confounders and/or effect modifiers. The between-study heterogeneity was also high in several pooled analyses, which was likely to be due to the difference in background populations, follow-up protocols, conditioning regimens, GvHD prophylaxis regimens, and stem cell sources across the included studies. In addition, when time to transplant is taken into account, patients who receive haplo-HSCT might have access to treatment more rapidly than those using other donors' sources. That might affect the outcome of transplantation. We found that some of the included studies reported no significant difference in the duration from diagnosis to

Study or Subgroup Events Total Weight M.H, Random, 95% CI Year M.H, Random, 95% CI Cho 2012 12 23 21 43 4.6% 1.14 [0.41, 3.16] 2012 Distasi 2014 9 32 31 108 6.0% 0.97 [0.40, 2.33] 2014 Churea 2015 34 192 617 1982 18.8% 0.48 [0.32, 0.70] 2016 Rashidi 2016 21 52 32 88 6.5% 1.01 [0.37, 2.78] 2017 Bashey 2018 13 33 27 57 6.0% 0.72 [0.30, 1.72] 2018 Santoro 2018 76 250 857 259 24.6% 0.88 [0.67, 1.17] 2018 Devillier 2018 7 33 12 30 39% 0.40 [0.13, 1.22] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 2014			Haple		MUE			Odds Ratio		Odds Ratio	
Di Stasi 2014 9 32 31 108 6.0% 0.97 [0.40, 2.33] 2014 Clurea 2015 34 192 617 1982 18.8% 0.48 [0.32, 0.70] 2016 How 2017 14 24 25 43 4.6% 1.01 [0.37, 2.78] 2017 Bashey 2018 13 33 2.7 57 6.0% 0.72 [0.30, 1.72] 2018 Santoro 2018 76 250 657 2589 24.6% 0.88 [0.67, 1.17] 2018 Dewiller 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Uncentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] Total events 236 1821 Heterogeneity: Tau ² = 0.04; Ch ² = 12.65, df = 9 (P = 0.18); P = 29% Test for overall effect Z = 1.71 (P = 0.09) Haplo MUD Odds Ratio Odds Ratio Study or Subgroup Events Total Weight M.H.Random, 95% CI Year Cho 2012 11 23 22 43 3.9% 0.48 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Clurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Dewiller 2018 8 33 10 30 3.4% 0.68 [0.36, 1.25] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2016 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 8 29 87 37 87 9.7% 0.68 [0.36, 1.26] 2018 Journal 9 2018 228 2438 Heterogeneity: Tau ² = 0.02, Ch ² = 10.64, df = 9 (P = 0.30); P = 15% Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73] Jotal events 228 2438 Heterogeneity: Tau ² = 0.02, Ch ² = 10.64, df = 9 (P = 0.30); P = 15% Test for overall effect Z = 4.88 (P < 0.00001)	-	Study or Subgroup								M-H, Random, 95% Cl	
Clurea 2015 34 192 617 1982 18.8% 0.48 0.32 0.70 2015 Rashid 2016 21 52 32 88 8.5% 1.19 [0.59, 2.40] 2016 Bashey 2018 13 33 27 57 6.0% 0.72 [0.30, 1.72] 2018 Deviller 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Santoro 2018 76 250 87 27.89 9.7% 0.35 [0.50, 1.81] 2018 Currentino 2018 24 74 172 556 1.07 [0.64, 1.80] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 0.05 0.2 0.5 1.07 0.84 0.32, 2.41 2018 Total events 236 1821 MUD Odds Ratio MUD more aGVHD Odds Ratio Study or Subgroup Events Total Weight M.44, Random, 95% CI Year MUD more aGVHD Distasi 2014 61 92 92											
Rashidi 2016 21 52 32 88 8.5% 1.19 [0.59, 2.40] 2016 How 2017 14 24 25 43 4.6% 1.01 [0.37, 2.78] 2017 Bashey 2018 13 33 27 57 6.0% 0.72 [0.30, 1.72] 2018 Santoro 2018 76 250 857 2589 24.6% 0.88 [0.67, 1.17] 2018 Deviller 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Lorentino 2018 26 87 27 9.7% 0.95 [0.50, 1.81] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 1 Total events 236 1821 Heterogeneity: Tau" = 0.04; Chi" = 12.65, df = 9 (P = 0.18); P = 29% MUD more aGVHD MUD more aGVHD Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Year Cho 2012 11 23 22 43 3.9% 0.88 [0.32, 2.41] 2012 0.5 12 Di Stasi 20		Di Stasi 2014	-					0.97 [0.40, 2.33]			
How 2017 14 24 25 43 4.6% 1.01 [0.37, 2.78] 2017 Bashey 2018 13 33 27 57 6.0% 0.72 [0.30, 1.72] 2018 Santoro 2018 76 250 857 2589 24.6% 0.88 [0.67, 1.17] 2018 Devillier 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Sun 2018 26 87 27 87 9.7% 0.95 [0.50, 1.81] 2018 Lorentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% Cl) 800 5583 100.0% 0.82 [0.65, 1.03] Total events 236 1821 Heterogeneity: Tau" = 0.04; Chi" = 12.65, df = 9 (P = 0.18); I" = 29% Test for overall effect Z = 1.71 (P = 0.09) MUD Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year Cho 2012 11 23 22 43 3.9% 0.48 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashid 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.21, 1.92] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Total events 228 74 200 556 13.4% 0.96 [0.32, 1.85] 2018 Total events 228 2438 Heterogeneity: Tau" = 0.02; Chi" = 10.84; df = 9 (P = 0.30); I" = 15% Total events 228 2438 Heterogeneity: Tau" = 0.02; Chi" = 10.84; df = 9 (P = 0.30); I" = 15% Total (95% Cl) 800 5583 100.0% 0.59 [0.48, 0.73] Total events 228 2438 (H = 0.00001)			34								
Bashey 2018 13 33 27 57 6.0% $0.72 [0.30, 1.72]$ 2018 Santoro 2018 76 250 857 2589 24.6% 0.88 [0.67, 1.17] 2018 Devillier 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Lorentino 2018 26 87 27 87 9.7% 0.95 [0.50, 1.81] 2018 Lorentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% Cl) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 12 Total (95% Cl) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 2 Test for overall effect: Z = 1.71 (P = 0.09) Events Total Weight M-H, Random, 95% Cl Year MUD more aGVHD Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 4 4 4 2 3 4 4 4 2 2 2 <td></td>											
Santoro 2018 76 250 857 2589 24.6% 0.88 [0.67, 1.17] 2018 Dewillier 2018 7 33 12 30 3.9% 0.40 [0.13], 1.22 2018 Sun 2018 26 87 27 87 9.7% 0.95 [0.50, 1.81] 2018 Lorentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 1.2 Total events 236 1821 1821 144 1472 165, df = 9 (P = 0.18); P = 29% 10.2 0.5 1.2 MUD more aGVHD Study or Subgroup Events Total Events Total Weight M-4, Random, 95% CI Year Cho 2012 11 23 22 13 3.9% 0.88 [0.32, 2.41] 2012 0.5 1.2 Di Stasi 2014 6 32 22 10.8 2.62.% 0.42 [0.31, 0.58] 2015 1.4 1.4 2.1 0.5 1.2 1.4 1.4 2.1		How 2017	14	24	25	43	4.6%	1.01 [0.37, 2.78]	2017		
Devillier 2018 7 33 12 30 3.9% 0.40 [0.13, 1.22] 2018 Sun 2018 26 87 27 87 9.7% 0.95 [0.50, 1.81] 2018 Lorentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 1.27 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03] 0.2 0.5 1.2 Heterogeneity: Tau" = 0.04; Chi" = 12.65, df = 9 (P = 0.18); P = 29% Test for overall effect: Z = 1.71 (P = 0.09) MUD more aGVHD MUD more aGVHD Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Year Cho 2012 11 23 22 43 3.9% 0.58 [0.32, 2.41] 2012 0.4 Gods Ratio Staisi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 How 2017 3 24 9 43 2.1% 0.54 [0.31, 2.22] 2017 <tr< td=""><td></td><td>Bashey 2018</td><td>13</td><td>33</td><td>27</td><td>57</td><td>6.0%</td><td>0.72 [0.30, 1.72]</td><td>2018</td><td></td></tr<>		Bashey 2018	13	33	27	57	6.0%	0.72 [0.30, 1.72]	2018		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Santoro 2018	76	250	857	2589	24.6%	0.88 [0.67, 1.17]	2018		
Lorentino 2018 24 74 172 556 13.2% 1.07 [0.64, 1.80] 2018 Total (95% CI) 800 5583 100.0% 0.82 [0.65, 1.03]		Devillier 2018	7	33	12	30	3.9%	0.40 [0.13, 1.22]	2018	· · · · · · · · · · · · · · · · · · ·	
Total (95% Cl) 800 5583 100.0% 0.82 [0.65, 1.03] Total events 236 1821 Heterogeneity: Tau ² = 0.04; Chi ² = 12.65, df = 9 (P = 0.18); I ² = 29% Image: Chi P = 0.04; Chi ² = 12.65, df = 9 (P = 0.18); I ² = 29% Test for overall effect: Z = 1.71 (P = 0.09) MUD Odds Ratio Odds Ratio <t< td=""><td></td><td>Sun 2018</td><td>26</td><td>87</td><td>27</td><td>87</td><td>9.7%</td><td>0.95 [0.50, 1.81]</td><td>2018</td><td></td></t<>		Sun 2018	26	87	27	87	9.7%	0.95 [0.50, 1.81]	2018		
Total events 236 1821 Heterogeneity: Tau ² = 0.04; Chi ² = 12.65, df = 9 (P = 0.18); l ² = 29% 0.2 0.5 1 2 Test for overall effect: Z = 1.71 (P = 0.09) MUD Odds Ratio MUD more aGVHD Haplo more aGVHD MUD more aGVHD Haplo more aGVHD Odds Ratio		Lorentino 2018	24	74	172	556	13.2%	1.07 [0.64, 1.80]	2018		
Heterogeneity: $Tau^2 = 0.04$; $Chi^2 = 12.65$, $df = 9$ (P = 0.18); P = 29% Test for overall effect: $Z = 1.71$ (P = 0.09) MUD Odds Ratio MUD more aGVHD Haplo more aGVHD MUD more aGVHD Haplo more aGVHD Odds Ratio Odd		Total (95% CI)		800		5583	100.0%	0.82 [0.65, 1.03]		•	
Test for overall effect: $Z = 1.71$ (P = 0.09) U.2 0.5 1 2 MUD Odds Ratio Study or Subgroup Events Total Weight M-H, Random, 95% CI Year MUD Odds Ratio Cho 2012 111 23 22 43 3.9% Odds Ratio Clivea 2012 111 23 22 AUUD Odds Ratio Clivea 2015 61 192 1043 1982 0.62 0.048 Ratio Clivea 2015 61 192 1043 0.82($0.33, 0.44$ 0.014 0 MUD Odds Ratio Clivea 2015 61 192 1043 0.42 ($0.31, 0.58$ 0.014 0.016 MUD Od		Total events	236		1821						
Test for overall effect: $Z = 1.71$ (P = 0.09) MUD more aGVHD Haplo more aGVHD MUD more aGVHD Haplo more aGVHD Study or Subgroup Events Total Odds Ratio Odds Ratio Cho 2012 11 23 22 43 3.9% Odds Ratio Odds Ratio Odds Ratio Odds Ratio <th col<="" td=""><td></td><td>Heterogeneity: Tau² =</td><td>0.04; Chi</td><td>= 12.6</td><td>65, df = 9</td><td>(P = 0.</td><td>18); I² = 2</td><td>9%</td><td></td><td></td></th>	<td></td> <td>Heterogeneity: Tau² =</td> <td>0.04; Chi</td> <td>= 12.6</td> <td>65, df = 9</td> <td>(P = 0.</td> <td>18); I² = 2</td> <td>9%</td> <td></td> <td></td>		Heterogeneity: Tau ² =	0.04; Chi	= 12.6	65, df = 9	(P = 0.	18); I ² = 2	9%		
Haplo MUD Odds Ratio M-H, Random, 95% CI Year M-H, Random, 95% CI Cho 2012 11 23 22 43 3.9% 0.88 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 20		Test for overall effect:	Z=1.71 (P = 0.0	9)					0.2 0.5 1 2 5	
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% Cl Cho 2012 11 23 22 43 3.9% 0.88 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Lorentino 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Total (95% Cl) 80 5583 100.0%										MUD more aGVHD Haplo more aGVHD	
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% Cl Cho 2012 11 23 22 43 3.9% 0.88 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Lorentino 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Total (95% Cl) 80 5583 100.0%											
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% Cl Cho 2012 11 23 22 43 3.9% 0.88 [0.32, 2.41] 2012 Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Lorentino 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Total (95% Cl) 80 5583 100.0%											
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			Hapl	0	MU			Odds Ratio		Odds Ratio	
Di Stasi 2014 6 32 32 108 4.2% 0.55 [0.21, 1.46] 2014 Ciurea 2015 61 192 1043 1982 26.2% 0.42 [0.31, 0.58] 2015 Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Santor 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.86] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% Cl) 800 5583 100.0% 0.59 [0.48, 0.73] Total events 228 2438 Heterogeneity: Tau ² = 0.02; Chi ² = 10.64, df = 9 (P = 0.30); I ² = 15% Test for overall effect: Z = 4.98 (P < 0.00001)		Study or Subaroup	•			Concerns and	Weight	and the second	Year		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	-		Events	Total	Events	Total		M-H, Random, 95% Cl			
Rashidi 2016 5 52 8 88 3.0% 1.06 [0.33, 3.44] 2016 How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.85] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73]	1	Cho 2012	Events 11	Total 23	Events 22	Total 43	3.9%	M-H, Random, 95% Cl 0.88 [0.32, 2.41]	2012		
How 2017 3 24 9 43 2.1% 0.54 [0.13, 2.22] 2017 Devillier 2018 8 33 10 30 3.4% 0.64 [0.21, 1.92] 2018 Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.85] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% Cl) 800 5583 100.0% 0.59 [0.48, 0.73] \bullet \bullet \bullet Total events 228 2438 10.64, df = 9 (P = 0.30); P = 15% 0.2 0.5 1 2 0.5 1 2 0.5 1 2 5 Total events 228 2438 10.64, df = 9 (P = 0.30); P = 15% 0.2 0.5 1 2 5		Cho 2012 Di Stasi 2014	Events 11 6	Total 23 32	Events 22 32	Total 43 108	3.9% 4.2%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46]	2012 2014		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Cho 2012 Di Stasi 2014 Ciurea 2015	Events 11 6 61	Total 23 32 192	Events 22 32 1043	Total 43 108 1982	3.9% 4.2% 26.2%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58]	2012 2014 2015		
Sun 2018 29 87 37 87 9.7% 0.68 [0.36, 1.25] 2018 Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.85] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73] Image: Comparison of the second o		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016	Events 11 6 61 5	Total 23 32 192 52	Events 22 32 1043 8	Total 43 108 1982 88	3.9% 4.2% 26.2% 3.0%	M-H, Random, 95% Cl 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44]	2012 2014 2015 2016		
Santoro 2018 66 250 1051 2589 28.9% 0.52 [0.39, 0.70] 2018 Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.85] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73] Total events 228 2438 Heterogeneity: Tau ² = 0.02; Chi ² = 10.64, df = 9 (P = 0.30); l ² = 15% Test for overall effect: Z = 4.98 (P < 0.00001)		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017	Events 11 6 61 5 3	Total 23 32 192 52 24	Events 22 32 1043 8 9	Total 43 108 1982 88 43	3.9% 4.2% 26.2% 3.0% 2.1%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22]	2012 2014 2015 2016 2017		
Bashey 2018 13 33 26 57 5.2% 0.78 [0.32, 1.85] 2018 Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73] Image: constraint of the second s		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018	Events 11 6 61 5 3 8	Total 23 32 192 52 24 33	Events 22 32 1043 8 9 10	Total 43 108 1982 88 43 30	3.9% 4.2% 26.2% 3.0% 2.1% 3.4%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92]	2012 2014 2015 2016 2017 2018		
Lorentino 2018 26 74 200 556 13.4% 0.96 [0.58, 1.60] 2018 Total (95% CI) 800 5583 100.0% 0.59 [0.48, 0.73] ◆ Total events 228 2438		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018	Events 11 6 61 5 3 8 29	Total 23 32 192 52 24 33 87	Events 22 32 1043 8 9 10 37	Total 43 108 1982 88 43 30 87	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25]	2012 2014 2015 2016 2017 2018 2018		
Total (95% Cl) 800 5583 100.0% 0.59 [0.48, 0.73] Total events 228 2438 Heterogeneity: Tau ² = 0.02; Chi ² = 10.64, df = 9 (P = 0.30); l ² = 15% 0.2 0.5 1 1 Test for overall effect: Z = 4.98 (P < 0.00001)		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018	Events 11 6 61 5 3 8 29 66	Total 23 32 192 52 24 33 87 250	Events 22 32 1043 8 9 10 37 1051	Total 43 108 1982 88 43 30 87 2589	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70]	2012 2014 2015 2016 2017 2018 2018 2018		
Total events 228 2438 Heterogeneity: Tau ² = 0.02; Chi ² = 10.64, df = 9 (P = 0.30); l ² = 15% 1 1 Test for overall effect: Z = 4.98 (P < 0.00001)		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018 Bashey 2018	Events 11 6 1 5 3 8 29 66 13	Total 23 32 192 52 24 33 87 250 33	Events 22 32 1043 8 9 10 37 1051 26	Total 43 108 1982 88 43 30 87 2589 57	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9% 5.2%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70] 0.78 [0.32, 1.85]	2012 2014 2015 2016 2017 2018 2018 2018 2018		
Heterogeneity: Tau ² = 0.02; Chi ² = 10.64, df = 9 (P = 0.30); l ² = 15% I		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018 Bashey 2018	Events 11 6 1 5 3 8 29 66 13	Total 23 32 192 52 24 33 87 250 33	Events 22 32 1043 8 9 10 37 1051 26	Total 43 108 1982 88 43 30 87 2589 57	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9% 5.2%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70] 0.78 [0.32, 1.85]	2012 2014 2015 2016 2017 2018 2018 2018 2018		
Test for overall effect: Z = 4.98 (P < 0.00001) U.2 U.5 1 2 5		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018 Bashey 2018 Lorentino 2018 Total (95% CI)	Events 11 6 61 5 3 8 29 66 13 26	Total 23 32 192 52 24 33 87 250 33 74	Events 22 322 1043 8 9 10 37 1051 26 200	Total 43 108 1982 88 43 30 87 2589 57 556	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9% 5.2% 13.4%	M-H, Random, 95% Cl 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70] 0.78 [0.32, 1.85] 0.96 [0.58, 1.60]	2012 2014 2015 2016 2017 2018 2018 2018 2018		
Test for overall effect: $Z = 4.98$ (P < 0.00001)		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018 Bashey 2018 Lorentino 2018 Total (95% CI) Total events	Events 11 6 61 5 3 8 29 66 13 26 228	Total 23 32 192 52 24 33 87 250 33 74 800	Events 22 322 1043 8 9 10 37 1051 26 200 2438	Total 43 108 1982 88 43 30 87 2589 57 556 5583	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9% 5.2% 13.4% 100.0%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70] 0.78 [0.32, 1.85] 0.96 [0.58, 1.60] 0.59 [0.48, 0.73]	2012 2014 2015 2016 2017 2018 2018 2018 2018		
		Cho 2012 Di Stasi 2014 Ciurea 2015 Rashidi 2016 How 2017 Devillier 2018 Sun 2018 Santoro 2018 Bashey 2018 Lorentino 2018 Total (95% CI) Total events Heterogeneity: Tau ² =	Events 11 6 61 5 3 8 29 66 13 26 13 26 228 0.02; Chi	Total 23 32 192 52 24 33 87 250 33 74 800 ² = 10.6	Events 22 32 1043 8 9 10 37 1051 26 200 2438 64, df = 9	Total 43 108 1982 88 43 30 87 2589 57 556 5583	3.9% 4.2% 26.2% 3.0% 2.1% 3.4% 9.7% 28.9% 5.2% 13.4% 100.0%	M-H, Random, 95% CI 0.88 [0.32, 2.41] 0.55 [0.21, 1.46] 0.42 [0.31, 0.58] 1.06 [0.33, 3.44] 0.54 [0.13, 2.22] 0.64 [0.21, 1.92] 0.68 [0.36, 1.25] 0.52 [0.39, 0.70] 0.78 [0.32, 1.85] 0.96 [0.58, 1.60] 0.59 [0.48, 0.73]	2012 2014 2015 2016 2017 2018 2018 2018 2018	M-H, Random, 95% CI	

Figure 7. Forest plots of studies that compared (A) acute GvHD and (B) chronic GvHD among patients who underwent haplo-HSCT versus MUD-HSCT.

Cl: confidence interval; GvHD: graft-versus-host disease; haplo: haploidentical; HSCT: hematopoietic stem cell transplantation; M-H: Mantel-Haenszel Method; MUD: matched unrelated donor.

the date of transplantation between the two groups of patients. However, the rest of the studies did not provide these data; we therefore cannot completely conclude that waiting time prior to HSCT was not significantly different between both groups.

Conclusion

The current study found that the OS and several secondary outcomes of patients with AML and MDS who received haplo-HSCT were not significantly different from MSD-HSCT and MUD-HSCT. This suggests that haplo-HSCT is a reasonable alternative. However, the primary studies included in this meta-analysis were observational in nature. Therefore, randomized-controlled trials are still needed to confirm the efficacy of haplo-HSCT.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The need to obtain ethical approval by an institutional board review was waived as this study did not directly involve human subjects.

Statement of Human and Animal Rights

This article does not contain any studies with human or animal subjects.

Statement of Informed Consent

Not applicable because this study did not directly involve human subjects.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Weerapat Owattanapanich https://orcid.org/0000-0002-1262-2005

Supplemental Material

Supplemental material for this article is available online.

References

- Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, Lenarsky C, Elashoff R, Zighelboim J, Feig SA. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985;102(3):285–291.
- Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332(4):217–223.
- Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96(13):4075–4083.
- 4. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–3666.
- 5. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dolken G, Becker C, Heyn S, Kliem C, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in highrisk acute myeloid leukaemia patients in first complete remission. Leukemia. 2009;23(4):635–640.
- Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–2361.
- Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology Am Soc Hematol Educ Program. 2016;2016(1): 478–484.
- Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M. HLA match likelihoods for hematopoietic stemcell grafts in the U.S. registry. N Engl J Med. 2014;371(4): 339–348.

- Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119(17):3908–3916.
- Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197–204.
- Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991–2000). Blood. 2003;102(4):1541–1547.
- Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47(1–3):65–77.
- Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
- Deotare U, Al-Dawsari G, Couban S, Lipton JH. G-CSFprimed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant. 2015;50(9): 1150–1156.
- Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Fan ZP, Wu DP, Huang XJ. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–3962.
- Kanakry CG, de Lima MJ, Luznik L. Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Semin Hematol. 2015;52(3):232–242.
- Appelbaum FR. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program. 2008:412–417.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009;339:b2535.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
- Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
- Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. West Sussex (UK): John Wiley & Sons; 2009.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414): 557–660.

- 23. Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10(1):134.
- 24. How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R. T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(4):648–653.
- 25. Devillier R, Legrand F, Rey J, Castagna L, Furst S, Granata A, Charbonnier A, Harbi S, d'Incan E, Pagliardini T, Faucher C, et al. HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison. Biol Blood Marrow Transplant. 2018;24(7):1449–1454.
- 26. Liu Y, Huang X, Fei Q, Xu L, Zhang X, Liu K, Chen Y, Chen H, Wang Y. Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Sci China Life Sci. 2019;62(5):691–697.
- 27. Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Socie G, Bourhis JH, Van Lint MT, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103(8):1317–1328.
- Cho BS, Yoon JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/ haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012;18(10):1552–1563.
- 29. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040.
- 30. Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R. Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center

review. Biol Blood Marrow Transplant. 2016;22(9): 1696–1701.

- 31. Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I, Piemontese S, Polge E, Houhou M, Huang XJ, Mohty M, et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Haematologica. 2016; 101(8):e352–354.
- 32. Lorentino F, Labopin M, Bernardi M, Ciceri F, Socie G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, et al. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018; 93(10):1236–1244.
- 33. Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kroger N, Einsele H, Eder M, Hallek M, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11(1):55.
- 34. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014; 20(12):1975–1981.
- 35. Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Bashey A, Solomon SR, Solh M. Comparison of outcomes following transplantation with T-replete HLAhaploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant. 2018;53(6):756–763.
- 36. Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, Santarone S, Gülbas Z, Blaise D, Messina G, Ghavamzadeh A, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017; 102(2):401–410.
- 37. Abdelhakim H, Abdel-Azim H, Saad A. Role of $\alpha\beta$ T cell depletion in prevention of graft versus host disease. Biomedicines. 2017;5(3):35.
- Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91.